申请人:Birch Alan Martin
公开号:US20110092547A1
公开(公告)日:2011-04-21
Compounds of formula (I), or pharmaceutically-acceptable salts and/or pro-drugs thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided,
wherein n is 0 to 3; p is 0 or 1; q is 0 to 2;
R
1
and R
2
are, for example, independently fluoro, chloro, bromo, cyano or (1-4C)alkyl;
X is —O—, —S— or —NRa— wherein Ra is hydrogen or (1-4C)alkyl;
R
A1
and R
A2
are, for example, independently hydrogen or (1-4C)alkyl;
Ring A is a di-linked ring or ring system chosen from (4-6C)cycloalkane, (7-10C)bicycloalkane and (8-12C)tricycloalkane each optionally substituted, for example, by one substituent selected from (1-4C)alkyl, (1-4C)alkoxy and (1-4C)alkoxy(1-4C)alkyl;
or Ring A is phenylene optionally substituted, for example, by up to four substituents selected from fluoro, chloro, bromo, cyano, (1-4C)alkyl, (1-4C)alkoxy and (1-4C)alkoxy(
1
-4C)alkyl; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.
提供公式(I)的化合物,或其药学上可接受的盐和/或前药,其抑制乙酰辅酶A:二酰基甘油酰基转移酶(DGAT1)活性,其中n为0至3;p为0或1;q为0至2;R1和R2例如独立地为氟、氯、溴、氰或(1-4C)烷基;X为—O—、—S—或—NRa—,其中Ra为氢或(1-4C)烷基;RA1和RA2例如独立地为氢或(1-4C)烷基;环A为二联环或环系统,选择自(4-6C)环烷、(7-10C)双环烷和(8-12C)三环烷,每个环可选地被一个取代基取代,所述取代基选择自(1-4C)烷基、(1-4C)烷氧基和(1-4C)烷氧基(1-4C)烷基;或环A为苯环,可选地被多达四个取代基取代,所述取代基选择自氟、氯、溴、氰、(1-4C)烷基、(1-4C)烷氧基和(1-4C)烷氧基(1-4C)烷基;以及它们的制备过程、含有它们的药物组合物和它们作为药物的用途。